Management of Generalized Granuloma Annulare Using Systemic Biologics and Small Molecules: An Evidence-Based Review

Abstract

Keywords

granuloma annulare biologic Janus kinase inhibitor small molecule systematic review

Get full access to this article

View all access options for this article.

References

Joshi

Duvic

. Granuloma annulare: an updated review of epidemiology, pathogenesis, and treatment options. Am J Clin Dermatol. 2022;23(1):37-50. doi:10.1007/s40257-021-00636-1

Min

, et al Granuloma annulare skin profile shows activation of T-helper cell type 1, T-helper cell type 2, and Janus kinase pathways. J Am Acad Dermatol. 2020;83(1):63-70. doi:10.1016/j.jaad.2019.12.028

Hwang

Lee

Okifo

Murphy

Damsky

. Retrospective assessment of immunologic and histologic heterogeneity in granuloma annulare by cytokine staining. Int J Dermatol. 2024;63(5):655-659. doi:10.1111/ijd.16998

Wang

Rahman

McGeary

, et al Treatment of granuloma annulare and suppression of proinflammatory cytokine activity with tofacitinib. J Allergy Clin Immunol. 2021;147(5):1795-1809. doi:10.1016/j.jaci.2020.10.012

Janus Kinase Inhibition in Granuloma Annulare. ClinicalTrials.gov identifier: NCT05650736. Updated 2023. Accessed February 14, 2024. https://classic.clinicaltrials.gov/ct2/show/NCT05650736

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

2.68 MB

0.03 MB

0.06 MB

0.03 MB